nach oben

Current Treatment Options in Gastroenterology

Erschienen in:

23.01.2018 | Inflammatory Bowel Disease (G Lichtenstein, Section Editor)

The Natural History of IBD: Lessons Learned

verfasst von: Petra Weimers, MD, PhD, Pia Munkholm, MD, DMSci

Erschienen in: Current Treatment Options in Gastroenterology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Inflammatory bowel diseases (IBD), which include Crohn’s disease (CD) and ulcerative colitis (UC), are chronic, relapsing diseases with unknown etiologies. The purpose of this review is to present the natural disease course evidenced in the latest epidemiology data.

Recent Findings

The prevalence of IBD is rapidly increasing, affecting five million patients worldwide with the highest incidence observed in Northern Europe and Northern America. It has been shown that both CD and UC patients are at an increased risk for developing cancer of the gastrointestinal tract compared to the general population. Though the disease course of IBD is unpredictable, the rate of surgical treatment has declined potentially as a consequence of the introduction of immunomodulators and new biologic treatment options.

Summary

Treatments with biological agents and/or immunosuppressive drugs as well as disease monitoring with eHealth devices seem to have a positive impact on the disease course. However, long-term follow-up studies are still lacking and therefore no reliable conclusions can be drawn as of yet. Medical compliance is paramount in the treatment of IBD, and continuous research focusing on approaches that increase compliance is also necessary.

Burisch J, Pedersen N, Čuković-Čavka S, et al. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut. 2014;63(4):588–97. https://doi.org/10.1136/gutjnl-2013-304,636.CrossRefPubMed

Ng SC, Tang W, Ching JY, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-Pacific Crohn’s and Colitis Epidemiology Study. Gastroenterology. 2013, 145(1):158–165.e2. https://doi.org/10.1053/j.gastro.2013.04.007.

Burisch J, Jess T, Martinato M, Lakatos PL. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013;7(4):322–37. https://doi.org/10.1016/j.crohns.2013.01.010.CrossRefPubMed

Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1785–94. https://doi.org/10.1053/j.gastro.2011.01.055. CrossRefPubMed

Latella G, Papi C. Crucial steps in the natural history of inflammatory bowel disease. World J Gastroenterol 2012;18(29):3790–3799. doi:https://doi.org/10.3748/wjg.v18.i29.3790.

Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361(21):2066–78. https://doi.org/10.1056/NEJMra0804647.CrossRefPubMedPubMedCentral

Benchimol EI, Fortinsky KJ, Gozdyra P, Van Den Heuvel M, Van Limbergen J, Griffiths AM. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis. 2011;17(1):423–39. https://doi.org/10.1002/ibd.21349.CrossRefPubMed

Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Publ Gr. 2015;12 https://doi.org/10.1038/nrgastro.2015.150.

Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev. Gastroenterol Hepatol. 2015;12(4):205–17. https://doi.org/10.1038/nrgastro.2015.34.CrossRefPubMed

10.

Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut. 1996;39(5):690–7. https://doi.org/10.1136/GUT.39.5.690. CrossRefPubMedPubMedCentral

11.

• Vegh Z, Burisch J, Pedersen N, et al. Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: results of the 2011 ECCO-EpiCom inception cohort. J Crohn’s Colitis. 2014;8(11):1506–15. https://doi.org/10.1016/j.crohns.2014.06.004. This article describes the latest epidemiological data on the initial disease course of IBD in Europe and Australia.CrossRef

12.

Loftus EV Jr. Update on the incidence and prevalence of inflammatory bowel disease in the United States. Gastroenterol Hepatol (N Y). 2016;12(11):704–7.PubMedCentral

13.

Bernstein CN, Wajda A, Svenson LW, et al. The Epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol J Gastroenterol. 2006;101:1559–68. https://doi.org/10.1111/j.1572-0241.2006.00603.x. CrossRef

14.

Herrinton LJ, Liu L, Lewis JD, Griffin PM, Allison J. Incidence and prevalence of inflammatory bowel disease in a Northern California Managed Care Organization, 1996–2002. Am J Gastroenterol J Gastroenterol. 2008;103:1998–2006. https://doi.org/10.1111/j.1572-0241.2008.01960.x.CrossRef

15.

Bitton A, Vutcovici M, Patenaude V, Sewitch M, Suissa S, Brassard P. Epidemiology of inflammatory bowel disease in Québec. Inflamm Bowel Dis. 2014;20(10):1770–6. https://doi.org/10.1097/MIB.0000000000000162.CrossRefPubMed

16.

Shivashankar R, Tremaine WJ, Harmsen WS, Loftus E V. Incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota from 1970 through 2010. Clin Gastroenterol Hepatol 2017;15(6):857–863. doi:https://doi.org/10.1016/j.cgh.2016.10.039.

17.

Hammer T, Nielsen KR, Munkholm P, Burisch J, Lynge E. The Faroese IBD Study: incidence of inflammatory bowel diseases across 54 years of population-based data. J Crohns Colitis. 2016;10(8):934–42. https://doi.org/10.1093/ecco-jcc/jjw050.CrossRefPubMedPubMedCentral

18.

•• Hammer T, Lophaven SN, Nielsen KR, et al. Inflammatory bowel diseases in Faroese-born Danish residents and their offspring: further evidence of the dominant role of environmental factors in IBD development. Aliment Pharmacol Ther. 2017;45(8):1107–14. https://doi.org/10.1111/apt.13975. The results of this article highlight the importance of environmental factors in the development of IBD.CrossRefPubMedPubMedCentral

19.

M’Koma AE. Inflammatory bowel disease: an expanding global health problem. Clin Med Insights Gastroenterol. 2013;6:33–47. https://doi.org/10.4137/CGast.S12731. PubMedPubMedCentral

20.

•• Kaplan GG, Ng SC. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology. 2017;152(2):313–321.e2. https://doi.org/10.1053/j.gastro.2016.10.020. This article describes the latest epidemiological data on IBD with an additional focus on possible preventing strategies.CrossRefPubMed

21.

Ng SC, Leung WK, Shi HY, et al. Epidemiology of inflammatory bowel disease from 1981 to 2014. Inflamm Bowel Dis. 2016;22(8):1954–60. https://doi.org/10.1097/MIB.0000000000000846.CrossRefPubMed

22.

Ng SC. Emerging trends of inflammatory bowel disease in Asia. Gastroenterol Hepatol (N Y). 2016;12(3):193–6.

23.

Leddin D, Tamim H, Levy AR. Decreasing incidence of inflammatory bowel disease in eastern Canada: a population database study. BMC Gastroenterol. 2014;14:140. https://doi.org/10.1186/1471-230X-14-140.CrossRefPubMedPubMedCentral

24.

Lophaven SN, Lynge E, Burisch J. The incidence of inflammatory bowel disease in Denmark 1980–2013: a nationwide cohort study. Aliment Pharmacol Ther. 2017;45(7):961–72. https://doi.org/10.1111/apt.13971. CrossRefPubMed

25.

Benchimol EI, Bernstein CN, Bitton A, et al. Trends in epidemiology of pediatric inflammatory bowel disease in Canada: distributed network analysis of multiple population-based provincial health administrative databases. Am J Gastroenterol. 2017;112(7):1120–34. https://doi.org/10.1038/ajg.2017.97.CrossRefPubMedPubMedCentral

26.

Virta LJ, Saarinen MM, Kolho K-L. Inflammatory bowel disease incidence is on the continuous rise among all paediatric patients except for the very young: a nationwide registry-based study on 28-year follow-up. J Crohn’s Colitis. 2017;11(2):150–6. https://doi.org/10.1093/ecco-jcc/jjw148.CrossRef

27.

Burisch J, Munkholm P. The epidemiology of inflammatory bowel disease. Scand J Gastroenterol. 2015;50(8):942–51. https://doi.org/10.3109/00365521.2015.1014407.CrossRefPubMed

28.

Burisch J, Pedersen N, Cukovic-Cavka S, et al. Initial disease course and treatment in an inflammatory bowel disease inception cohort in Europe. Inflamm Bowel Dis. 2014;20(1):36–46. https://doi.org/10.1097/01.MIB.0000436277.13917.c4. CrossRefPubMed

29.

Vester-Andersen MK, Prosberg MV, Jess T, et al. Disease course and surgery rates in inflammatory bowel disease: a population-based, 7-year follow-up study in the era of immunomodulating therapy. Am J Gastroenterol. 2014;109(5):705–14. https://doi.org/10.1038/ajg.2014.45. CrossRefPubMed

30.

Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology. 1994;107(1):3–11. https://doi.org/10.1016/0016-5085(94)90054-X.CrossRefPubMed

31.

Melesse DY, Lix LM, Nugent Z, et al. Estimates of disease course in inflammatory bowel disease using administrative data: a population-level study. J Crohn’s Colitis. 2016;11(5):jjw201. doi:https://doi.org/10.1093/ecco-jcc/jjw201.

32.

Ng SC, Zeng Z, Niewiadomski O, et al. Early course of inflammatory bowel disease in a population-based inception cohort study from 8 countries in Asia and Australia. Gastroenterology. 2016;150(1):86–95.e3. https://doi.org/10.1053/j.gastro.2015.09.005.CrossRefPubMed

33.

Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44(4):431–40. https://doi.org/10.1080/00365520802600961. CrossRefPubMed

34.

Eriksson C, Cao Y, Rundquist S, et al. Changes in medical management and colectomy rates: a population-based cohort study on the epidemiology and natural history of ulcerative colitis in Örebro, Sweden, 1963–2010. Aliment Pharmacol Ther. 2017;46(8):748–57. https://doi.org/10.1111/apt.14268. CrossRefPubMed

35.

Samuel S, Ingle SB, Dhillon S, et al. Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis. Inflamm Bowel Dis. 2013;19(9):1. https://doi.org/10.1097/MIB.0b013e31828c84c5. CrossRef

36.

Gollop JH, Phillips SF, Melton LJ, Zinsmeister AR. Epidemiologic aspects of Crohn’s disease: a population based study in Olmsted County, Minnesota, 1943–1982. Gut. 1988;29(1):49–56. https://doi.org/10.1136/gut.29.1.49.CrossRefPubMedPubMedCentral

37.

Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV. Risk factors associated with progression to intestinal complications of Crohn’s disease in a population-based cohort. Gastroenterology. 2010;139(4):1147–55. https://doi.org/10.1053/j.gastro.2010.06.070.CrossRefPubMedPubMedCentral

38.

Solberg IC, Vatn MH, Høie O, et al. Clinical course in Crohn’s disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5(12):1430–8. https://doi.org/10.1016/j.cgh.2007.09.002.CrossRefPubMed

39.

Lo B, Vester-Andersen MK, Vind I, et al. Changes in disease behaviour and location in patients with Crohn’s disease after seven years of follow-up: a Danish population-based inception cohort. J Crohn’s Colitis. 2017; https://doi.org/10.1093/ecco-jcc/jjx138.

40.

Gower-Rousseau C, Vasseur F, Fumery M, et al. Epidemiology of inflammatory bowel diseases: new insights from a French population-based registry (EPIMAD). Dig Liver Dis. 2013;45(2):89–94. https://doi.org/10.1016/j.dld.2012.09.005. CrossRefPubMed

41.

Schwartz DA, Loftus EV, Tremaine WJ, et al. The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology. 2002;122(4):875–80. https://doi.org/10.1053/gast.2002.32362. CrossRefPubMed

42.

Scharl M, Rogler G, Biedermann L. Fistulizing Crohn’s disease. Clin Transl Gastroenterol. 2017;8(7):e106. https://doi.org/10.1038/ctg.2017.33.CrossRefPubMedPubMedCentral

43.

Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn’s disease patients. Scand J Gastroenterol. 1995;30(7):699–706. https://doi.org/10.3109/00365529509096316.CrossRefPubMed

44.

Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. 2007;13(4):481–9. https://doi.org/10.1002/ibd.20036. CrossRefPubMed

45.

Ferrari L, Krane MK, Fichera A. Inflammatory bowel disease surgery in the biologic era. World J Gastrointest Surg. 2016;8(5):363–70. https://doi.org/10.4240/wjgs.v8.i5.363. CrossRefPubMedPubMedCentral

46.

Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2012;10(6):639–45. https://doi.org/10.1016/j.cgh.2012.01.010.CrossRefPubMed

47.

Jewel Samadder N, Valentine JF, Guthery S, et al. Colorectal cancer in inflammatory bowel diseases: a population-based study in Utah. Dig Dis Sci. 2017;62(8):2126–32. https://doi.org/10.1007/s10620-016-4435-4.CrossRefPubMed

48.

Söderlund S, Granath F, Broström O, et al. Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males. Gastroenterology. 2010;138(5):1697–1703.e2. https://doi.org/10.1053/j.gastro.2010.02.007.CrossRefPubMed

49.

Zhiqin W, Palaniappan S, Raja Ali RA. Inflammatory bowel disease-related colorectal cancer in the Asia-Pacific Region: past, present, and future. Intest Res. 2014;12(3):194. https://doi.org/10.5217/ir.2014.12.3.194.CrossRefPubMedPubMedCentral

50.

Claessen MMH, Vleggaar FP, Tytgat KMAJ, Siersema PD, van Buuren HR. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 2009;50(1):158–164. doi:https://doi.org/10.1016/j.jhep.2008.08.013.

51.

Hovde Ø, Høivik ML, Henriksen M, Solberg IC, Småstuen MC, Moum BA. Malignancies in patients with inflammatory bowel disease: results from 20 years of follow-up in the IBSEN Study. J Crohn’s Colitis. 2016;11(5):jjw193. https://doi.org/10.1093/ecco-jcc/jjw193.CrossRef

52.

Kappelman MD, Farkas DK, Long MD, et al. Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. Clin Gastroenterol Hepatol. 2014;12(2):265–273.e1. https://doi.org/10.1016/j.cgh.2013.03.034.CrossRefPubMed

53.

Jess T, Gamborg M, Matzen P, Munkholm P, Sorensen TIA. Increased risk of intestinal cancer in Crohn’s disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol. 2005;100(12):2724–9. https://doi.org/10.1111/j.1572-0241.2005.00287.x. CrossRefPubMed

54.

Bojesen RD, Andersson M, Riis LB, Nielsen OH, Jess T. Incidence of, phenotypes of and survival from small bowel cancer in Denmark, 1994–2010: a population-based study. J Gastroenterol. 2016;51(9):891–9. https://doi.org/10.1007/s00535-016-1171-7.CrossRefPubMed

55.

Dahlin Bojesen R, Bojesen D, Riis LB, Høgdall E, Nielsen OH, Jess T. Inflammatory bowel disease and small bowel cancer risk, clinical characteristics, and histopathology: a population-based study. Clin Gastroenterol Hepatol. 2017; https://doi.org/10.1016/j.cgh.2017.06.051.

56.

Piton G, Cosnes J, Monnet E, et al. Risk factors associated with small bowel adenocarcinoma in Crohn’s disease: a case-control study. Am J Gastroenterol. 2008;103(7):1730–6. https://doi.org/10.1111/j.1572-0241.2008.01847.x. CrossRefPubMed

57.

Pedersen N, Duricova D, Elkjaer M, Gamborg M, Munkholm P, Jess T. Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol. 2010;105(7):1480–7. https://doi.org/10.1038/ajg.2009.760.CrossRefPubMed

58.

Algaba A, Guerra I, Castaño A, et al. Risk of cancer, with special reference to extra-intestinal malignancies, in patients with inflammatory bowel disease. World J Gastroenterol. 2013;19(48):9359–65. https://doi.org/10.3748/wjg.v19.i48.9359. CrossRefPubMedPubMedCentral

59.

Lam GY, Halloran BP, Peters AC, Fedorak RN. Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: lessons from other inflammatory disorders. World J Gastrointest Pathophysiol. 2015;6(4):181–92. https://doi.org/10.4291/wjgp.v6.i4.181. CrossRefPubMedPubMedCentral

60.

Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374(9701):1617–25. https://doi.org/10.1016/S0140. CrossRefPubMed

61.

Mariette X, Tubach F, Bagheri H, et al. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis. 2010;69(2):400–8. https://doi.org/10.1136/ard.2009.117762. CrossRefPubMed

62.

Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7(8):874–81. https://doi.org/10.1016/j.cgh.2009.01.004.CrossRefPubMedPubMedCentral

63.

Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9(1):36–41.e1. https://doi.org/10.1016/j.cgh.2010.09.016.CrossRefPubMed

64.

Selvaraj SA, Chairez E, Wilson LM, Lazarev M, Bass EB, Hutfless S. Use of case reports and the Adverse Event Reporting System in systematic reviews: overcoming barriers to assess the link between Crohn’s disease medications and hepatosplenic T-cell lymphoma. Syst Rev. 2013;2:53. https://doi.org/10.1186/2046-4053-2-53.CrossRefPubMedPubMedCentral

65.

Jess T, Winther KV, Munkholm P, Langholz E, Binder V. Mortality and causes of death in Crohn’s disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Gastroenterology. 2002;122(7):1808–14. https://doi.org/10.1053/gast.2002.33632.CrossRefPubMed

66.

Ekbom A, Helmick CG, Zack M, Holmberg L, Adami H-O. Survival and causes of death in patients with inflammatory bowel disease: a population-based study. Gastroenterology. 1992;103(3):954–60. https://doi.org/10.5555/URI:PII:001650859290029X. CrossRefPubMed

67.

Wolters FL, Russel MG, Sijbrandij J, et al. Crohn’s disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort. Gut. 2006;55(4):510–8. https://doi.org/10.1136/gut.2005.072793.CrossRefPubMedPubMedCentral

68.

Jess T, Loftus EV, Harmsen WS, et al. Survival and cause specific mortality in patients with inflammatory bowel disease: a long term outcome study in Olmsted County, Minnesota, 1940–2004. Gut. 2006;55(9):1248–54. https://doi.org/10.1136/gut.2005.079350. CrossRefPubMedPubMedCentral

69.

Hovde Ø, Kempski-Monstad I, Småstuen MC, et al. Mortality and causes of death in Crohn’s disease: results from 20 years of follow-up in the IBSEN study. Gut. 2014;63(5):771–5. https://doi.org/10.1136/gutjnl-2013-304,766.CrossRefPubMed

70.

Manninen P, Karvonen A-L, Huhtala H, et al. Mortality in ulcerative colitis and Crohn’s disease. A population-based study in Finland. J Crohn’s Colitis. 2012;6(5):524–8. https://doi.org/10.1016/j.crohns.2011.10.009.CrossRef

71.

Romberg-Camps M, Kuiper E, Schouten L, et al. Mortality in inflammatory bowel disease in the Netherlands 1991–2002. Inflamm Bowel Dis. 2010;16(8):1397–410. https://doi.org/10.1002/ibd.21189. CrossRefPubMed

72.

Bewtra M, Kaiser LM, TenHave T, Lewis JD. Crohn’s disease and ulcerative colitis are associated with elevated standardized mortality ratios. Inflamm Bowel Dis. 2013;19(3):599–613. https://doi.org/10.1097/MIB.0b013e31827f27ae.CrossRefPubMedPubMedCentral

73.

Jess T, Frisch M, Simonsen J. Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010. Clin Gastroenterol Hepatol. 2013;11(1):43–8. https://doi.org/10.1016/j.cgh.2012.09.026.CrossRefPubMed

74.

Winther KV, Jess T, Langholz E, Munkholm P, Binder V. Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County. Gastroenterology. 2003;125(6):1576–82. https://doi.org/10.1053/J.GASTRO.2003.09.036.CrossRefPubMed

75.

Jess T, Gamborg M, Munkholm P, TI a S. Overall and cause-specific mortality in ulcerative colitis: meta-analysis of population-based inception cohort studies. Am J Gastroenterol. 2007;102(3):609–17. https://doi.org/10.1111/j.1572-0241.2006.01000.x.CrossRefPubMed

76.

Elkjaer M, Shuhaibar M, Burisch J, et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided “Constant-care” approach. Gut. 2010;59(12):1652–61. https://doi.org/10.1136/gut.2010.220160. CrossRefPubMed

77.

Pedersen N, Thielsen P, Martinsen L, et al. eHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis. Inflamm Bowel Dis 2014;20(12):2276–22285. doi:https://doi.org/10.1097/MIB.0000000000000199.

78.

Elkjaer M. E-health: Web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Dan Med J. 2012;59(7):B4478.

79.

Huang VW, Reich KM, Fedorak RN. Distance management of inflammatory bowel disease: systematic review and meta-analysis. World J Gastroenterol. 2014;20(3):829. https://doi.org/10.3748/wjg.v20.i3.829.CrossRefPubMedPubMedCentral

80.

Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut. 1998;43(1):29–32. https://doi.org/10.1136/gut.43.1.29.CrossRefPubMedPubMedCentral

81.

Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet. 1980;315(8167):514. https://doi.org/10.1016/S0140-6736(80)92767-1.CrossRef

82.

Rungoe C, Langholz E, Andersson M, et al. Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979–2011. Gut. 2014;63(10):1607–16. https://doi.org/10.1136/gutjnl-2013-305,607.CrossRefPubMed

Titel: The Natural History of IBD: Lessons Learned
verfasst von: Petra Weimers, MD, PhD
Pia Munkholm, MD, DMSci
Publikationsdatum: 23.01.2018
Verlag: Springer US
Erschienen in: Current Treatment Options in Gastroenterology / Ausgabe 1/2018
Print ISSN: 1092-8472
Elektronische ISSN: 1534-309X
DOI: https://doi.org/10.1007/s11938-018-0173-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

VHF-Ablation nützt wohl nur bei reduzierter Auswurfleistung

02.05.2024 Ablationstherapie Nachrichten

Ob die Katheterablation von Vorhofflimmern bei Patienten mit Herzinsuffizienz die Komplikationsraten senkt, scheint davon abzuhängen, ob die Auswurfleistung erhalten ist oder nicht. Das legen die Ergebnisse einer Metaanalyse nahe.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Biosimilars in the Treatment of Inflammatory Bowel Disease: Supporting Evidence in 2017

Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease

Management of Serrated Polyps of the Colon

Updates on Women’s Health Issues in Patients with Inflammatory Bowel Disease

Management of Anemia in Patients with Inflammatory Bowel Disease (IBD)